News – Page 441 – Endpoints News

Gilead calls dibs on a PhI bispecific, hands over $60M to cash-strapped MacroGenics

3 years ago

Covid-19 roundup: Moderna rewrites agreement with Gavi; Bavarian Nordic touts PhII booster results

3 years ago

SpringWorks’ first awareness campaign resonates for patients with rare soft tissue tumor

3 years ago

Updated: Milestone Pharma claims PhIII redemption for its once-failed heart drug, putting it on a path to the FDA

3 years ago

Josh Bilenker, Jeff Engelman quiet on everything behind their $735M 'outer edge' startup

3 years ago

NeuBase lays off 60% of employees as it swaps out antisense focus for gene editing tech endorsed by George Church

3 years ago

Former Tillman Gerngross Covid-19 antibody startup cuts costs and headcount again, one month after rebrand

3 years ago

BIO in tumult as CEO abruptly exits; Some good PhIII news; Data issues still plague Novartis' gene therapy; Hot ...

3 years ago

Biohaven raises OCD awareness using real patients in clinical trial ad campaign

3 years ago

CHMP offers positive opinion for two high-profile drugs as part of latest batch of recommendations

3 years ago

Ensuring consistency in product quality: How FDA's requests for more info will be formalized

3 years ago

‘Pharma burnout’: Industry reputation slumps in first half of 2022, study finds

3 years ago

Supreme Court rejects Novartis' request for stay in Gilenya patent battle

3 years ago

President Biden offers another push on drug price savings via executive order

3 years ago

Biosimilar approvals on the rise after a two-year slump — Amgen report

3 years ago

Inotrem’s septic shock drug passes mid-stage test — but only for some patients

3 years ago

FDA punts Travere's rare kidney disease NDA for three months, requesting REMS update

3 years ago

Six biotechs merge to take on BridgeBio, Abeona in 'butterfly skin' disease, with eyes also set on Duchenne

3 years ago

Imara puts an end to its struggles as OrbiMed, 5AM-backed precision oncology player rides the shell to Nasdaq

3 years ago

Former Voyager CEO Andre Turenne makes a comeback with Atlas-backed covalent drug biotech

3 years ago

'Been through a lot': New Passage Bio CEO talks about 'rising tide'; Back in business with the FDA, BioMarin finds ...

3 years ago

A French biotech nabs Series A to see if it can carve a role in the ADC space

3 years ago

David Liu's biotech shoots for $150M+ IPO raise to develop CRISPR 3.0

3 years ago

Acadia draws attention to Rett syndrome with patient artist’s work and a portrait mosaic

3 years ago

First page Previous page 438 439 440441442 443 444 Next page Last page